Bicara Therapeutics Inc.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies for people with solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed antibody with a TGF-β ligand trap, designed to target tumors and inhibit TGF-β signaling. The therapy is being studied in head and neck squamous cell carcinoma, including in combination with pembrolizumab, and in other cancer types such as colorectal and cutaneous squamous cell carcinoma. Bicara also conducts clinical research into potential uses in anal squamous cell carcinoma. Bicara’s activities focus on developing drug candidates rather than marketing approved products. It is conducting a Phase 2/3 pivotal trial of ficerafusp alfa with pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, as well as other clinical studies. Bicara is headquartered in Boston, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BCAX in the last 30 days.
See all $BCAX insider activity →Morgan Stanley kept Bicara Therapeutics at Overweight but reduced its price target to $30 from $41, citing a 26.8% decrease. The new target suggests a 200.6% upside from the Nov 9 close of $9.98. Recent analyst price targets for the company range from $8 to $43.
Stifel kept its Buy rating on Bicara Therapeutics but cut its price target to $43 from $45, citing a 4.4% decrease. The new target suggests a 330.9% upside from the Nov 9 closing price of $9.98. Recent analyst price targets for the company range from $8 to $37.
Citizens reiterated a Market Outperform rating and $31.00 price target for Bicara Therapeutics (BCAX), citing trial progress and cash position. The stock trades at $9.98, up 11% in a week. Bicara reported Q3 2026 results, with $442.3M in cash and increased R&D spending. The company expects initial trial data in January 2027.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning BCAX (Bicara Therapeutics Inc.). Coverage has been balanced: 2 bullish, 2 neutral, and 2 bearish.
Recent BCAX coverage spans financial news, earnings and market movers.
Morgan Stanley kept Bicara Therapeutics at Overweight but reduced its price target to $30 from $41, citing a 26.8% decrease. The new target suggests a 200.6% upside from the Nov 9 close of $9.98. Recent analyst price targets for the company range from $8 to $43.
Stifel kept its Buy rating on Bicara Therapeutics but cut its price target to $43 from $45, citing a 4.4% decrease. The new target suggests a 330.9% upside from the Nov 9 closing price of $9.98. Recent analyst price targets for the company range from $8 to $37.
Analyst upgrade may drive buying interest.
BTIG maintained its Buy rating on Bicara Therapeutics but reduced its price target from $39 to $37, representing a 5.1% decrease. The new target suggests a 270.7% upside from the stock's Nov 9 close of $9.98. Recent analyst price targets for the company range from $8 to $39.
Bicara Therapeutics reported Q3 2026 earnings, focusing on FICERA for HPV-negative head and neck cancer. Management highlighted 80% tumor shrinkage in 80% of Phase Ib responders. The FORTIFI-HN01 trial is on track for mid-2027 interim analysis. Cash runway extends into 2029. R&D expenses rose to $56.5M. The company aims to differentiate FICERA with durable responses and survival data.
AlphAI scores every news story that mentions BCAX with an AI model for sentiment and relevance, and aggregates insider trades from Bicara Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley kept Bicara Therapeutics at Overweight but reduced its price target to $30 from $41, citing a 26.8% decrease. The new target suggests a 200.6% upside from the Nov 9 close of $9.98. Recent analyst price targets for the company range from $8 to $43.
Stifel kept its Buy rating on Bicara Therapeutics but cut its price target to $43 from $45, citing a 4.4% decrease. The new target suggests a 330.9% upside from the Nov 9 closing price of $9.98. Recent analyst price targets for the company range from $8 to $37.
Citizens reiterated a Market Outperform rating and $31.00 price target for Bicara Therapeutics (BCAX), citing trial progress and cash position. The stock trades at $9.98, up 11% in a week. Bicara reported Q3 2026 results, with $442.3M in cash and increased R&D spending. The company expects initial trial data in January 2027.
BTIG maintained its Buy rating on Bicara Therapeutics but reduced its price target from $39 to $37, representing a 5.1% decrease. The new target suggests a 270.7% upside from the stock's Nov 9 close of $9.98. Recent analyst price targets for the company range from $8 to $39.
Bicara Therapeutics reported Q3 2026 earnings, focusing on FICERA for HPV-negative head and neck cancer. Management highlighted 80% tumor shrinkage in 80% of Phase Ib responders. The FORTIFI-HN01 trial is on track for mid-2027 interim analysis. Cash runway extends into 2029. R&D expenses rose to $56.5M. The company aims to differentiate FICERA with durable responses and survival data.
Bicara Therapeutics (BCAX) plans an interim analysis for mid-2027. The company reports a $442.3M cash runway extending into the first half of 2029, according to the company.
Bicara Therapeutics (BCAX) reported Q3 earnings, highlighting FICERA's potential in HPV-negative head and neck cancer. Key data includes a 54% objective response rate and 21-month median overall survival. The company expects funding to last into 2029. Bicara is also studying FICERA in colorectal cancer and plans to present data in 2027.
Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 Enrolling FORTIFI-FLEX alternate do
Goldman Sachs downgraded Bicara Therapeutics (BCAX) to Sell with a $8.00 price target, citing competitive risks from Genmab's petosemtamab. BCAX trades at $9.73, down 44.6% in a week. Other analysts maintain Buy ratings with higher targets. Bicara expects Phase 3 trial results in mid-2027.
Wedbush kept Bicara Therapeutics at Outperform but lowered its price target to $24 from $33, a 27.3% decrease. This implies a 145.9% upside from the Oct 28 close of $9.76.
